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Heart failure is a very common disease, with severe morbidity and mortality, and a frequent reason of hospitalization. Anemia and
aconcurrentrenalimpairmentaretwomajorriskfactorscontributingtotheseverityoftheoutcomeandconsistofthecardiorenal
anemia syndrome. Anemia in heart failure is complex and multifactorial. Hemodilution, absolute or functional iron deﬁciency,
activation of the inﬂammatory cascade, and impaired erythropoietin production and activity are some pathophysiological
mechanisms involved in anemia of the heart failure. Furthermore other concomitant causes of anemia, such as myelodysplastic
syndrome and chemotherapy, may worsen the outcome. Based on the pathophysiology of cardiac anemia, there are several
therapeutic options that may improve hemoglobin levels, tissues’ oxygenation, and probably the outcome. These include
administration of iron, erythropoiesis-stimulating agents, and blood transfusions but still the evidence provided for their use
remains limited.
1.Introduction
Cardiovascular diseases are among the most frequent causes
of death worldwide [1, 2]. Heart failure is an enormous me-
dical and societal burden and a leading cause of hospita-
lization. It is estimated that 2.6 millions hospitalizations an-
n u a ll yi nt h eU S Aa r ed u et oh e a rtf a i l u r ea sap ri m a ryo rs e c -
ondary diagnosis [3].
Inthelast19yearstheroleofseveralimmunological,me-
tabolic, and neurohormonal abnormalities has been recog-
nized in the pathophysiology and progression of the conges-
tive heart failure (CHF) [4, 5]. Among them, anemia and re-
nal failure seem to be major risk factors for an adverse out-
come. The cardio renal anemia syndrome (CRAS) represents
a pathological triangle in which the primary failing organ is
the heart or the kidney and the dysfunction of one organ
leads to dysfunction of the other [6]. The presence of anemia
or renal dysfunction increases morbidity and mortality in
patients with heart failure. It seems that there is an impair-
ed mechanism operating between congestive heart failure,
chronic kidney disease (CKD), and anemia, where each
mightcauseorworsentheother.Therefore,correctionofan-
emia would be a major part of this vicious circle in the
reductionoftheseverityoftheheartfailure[6].Thiscouldbe
explained by the fact that a signiﬁcant feature of the conges-
tive heart failure is impaired energy metabolism and there-
fore the failing heart is an energy-starved heart [7]. Oxygen
delivery through hemoglobin (Hb) is essential for energy
production and improvement of Hb levels could also im-
prove energy production in cardiomyocytes. Simultaneously
energy-sparing treatments may also improve the prognosis
[7].
2. Epidemiology of Anemia in Heart Failure
Using the historical deﬁnition by the World Health Organi-
zation, anemia is deﬁned when Hb concentration is less than
13g/dLformenorlessthan12g/dLforwomen[8].However,
particularly in the setting of heart failure, this deﬁnition has
not been subjected to rigorous clinical validation and its
appropriateness and clinical applicability continues to be de-
bated [9]. Therefore, some investigators use more conserva-
tive deﬁnitions (e.g., <12g/dL for men and <11g/dL for
women) to ensure a higher conﬁdence in capturing the af-
fecting population [10].2 ISRN Hematology
Anemia is prevalent in patients with CHF but the exact
r a t e sv a r yw i d e l y[ 11]. A recent meta-analysis of 153,180 pa-
tients with CHF, reported in 34 published studies from 2001
to2007,estimatedtheprevalenceofanemiatobe37.2%(10–
49%) [10]. Similarly, the latest prospective STAMINA-HFP
(Study of Anemia in a Heart Failure Population) Registry
estimated a prevalence of 34% [11]. The variability in the
estimatedprevalenceofanemiaispartlyattributabletouseof
diﬀerent deﬁnitions of anemia, whereas patients in the acute
decompensated states experience more dilutional anemia
and therefore the prevalence may be increased. Patients with
CHF and anemia tend to be older than their nonanemic
counterparts [12], whereas, in patients less than 55 years, the
age of anemic and nonanemic patients does not appear to
diﬀer [13]. Concerning the gender, in studies of CHF and
anemia enrolling a preponderance of men, the proportion
of women steadily increases as Hb concentration falls to the
point that women can predominate among patients with
CHF and severe anemia [14].
One of the most frequent comorbid conditions in pa-
tientswithCHFisCKD(asdeﬁnedbyanestimatedglomeru-
larﬁltrationrate(eGFR)<90mL/min−1/1.72m−2).CHFand
CKD share some common causes (e.g., hypertension), feat-
ures (e.g., malnutrition, impaired performance status), and
risk factors (e.g., older age). In a meta-analysis of 16 studies,
it was found that 63% of 80,098 patients with CHF had some
degree of concomitant impaired renal function and 29% of
them had severe CKD. This is associated with an increased
risk of adverse outcome [15], being probably a stronger
predictor of mortality than ejection fraction (EF) or New
York Heart Association (NYHA) functional classes [16]. An-
emia is more prevalent when CHF and CKD coexist in both
ambulatory and hospitalized settings [17]. In large CHF
registries the degree of anemia closely parallels to eGFR,
although primary renal disease is relatively uncommon in
CHF [17, 18]. This justiﬁes that kidneys play a major role
in the pathophysiology of anemia in CHF. It is important
that patients with CHF and CKD develop anemia in higher
values of eGFR than patients with CKD alone. This provides
indirect evidence that other factors than CKD are involved in
the pathophysiology of anemia of CHF [19].
Anemia exacerbates symptoms of heart failure. There is
an impaired mechanism in which tissue hypoxia and release
ofnitricoxide(NO)causedecreasedarteriolarresistanceand
peripheral vasodilatation. These in turn lead to decreased
blood pressure, increased sympathetic activation, renal vaso-
constriction,reducedrenalfunction,andactivationofrenin-
angiotensin aldosterone system. The results are production
ofantidiuretichormone,ﬂuidretention,leftventricular(LV)
hypertrophy and dilation, worsening of heart failure, release
of brain natriuretic peptide (BNP), and signs from stress
on myocardium. The ﬁnal outcome, completing the vicious
circle, is further anemia. This, however, implies that in the
presence of volume overload there might be a decrease in
Hb concentration and also oxygen content, although red cell
mass remains stable [20]. The patient complains of shortness
of breath, tachycardia, dizziness, faintness, and fatigue.
Therefore, the presence of anemia is tightly linked to clin-
ical severity of CHF. Symptomatic deterioration and ﬂuid
retention inevitably lead to hospitalization. Thus, there is a
greater prevalence of anemia in hospitalized patients than
ambulatory ones [14]. On the other hand, the presence of
more advanced NYHA functional classes has been associated
with greater prevalence of anemia [21, 22]. Furthermore,
anemic patients with CHF have more commonly diabetes
mellitus and more advance disease, with higher NYHA class
and more severe symptoms. Those symptoms include low-
er exercise capacity, worse quality-of-life scores, greater per-
ipheral edema, lower dry weight and blood pressure, higher
use of diuretics and other cardiovascular medications, and
worse neurohormonal proﬁle (such as renal dysfunction,
high BNP and C-reactive protein, low serum albumin)
(range, 30% to 61% versus range, 4% to 23% for less
symptomatic ambulatory patients) [23, 24]. It is remarkable
that anemia does not seem to be related to LV dysfunction,
whereas in few studies Hb levels were inversely related to EF.
That means that patients with lower values of Hb had higher
EF, whereas increase of Hb could decrease LVEF, especially in
CKD, in a dose-dependent manner [22, 25–27].
Finally, most studies indicate that the prevalence of
anemia is increased in patients with CHF who also have co-
morbid kidney disease, advanced age, and more severe sym-
ptomswhencomparedtolesssymptomaticambulatorypop-
ulations [23].
3.Pathophysiology ofAnemiainHeart Failure
The major factors contributing to CHF-related anemia in-
volve CKD, renin-angiotensin system, hematinic abnormal-
ities, mainly iron deﬁciency, chronic inﬂammation, and he-
modilution (Figure 1).
A major factor contributing to anemia of CHF is kidney
dysfunction, being associated with the cardiac disorder. The
renal damage in the CHF is mainly hypoxic, due to reduc-
ed renal ﬂow, caused by the reduced cardiac output [14, 24].
Hypoxia induces erythropoietin (EPO) production by per-
itubular ﬁbroblasts, although renal blood ﬂow in CHF is
relatively maintained until the late stages of the syndrome,
especially when receiving angiotensin-converting enzyme
(ACE) inhibition. Nevertheless, EPO production does not
seemtocorrelatewitheﬀectiverenalplasmaﬂow.Itonlycor-
relates weakly with eGFR. This suggests that renal dysfunc-
tion plays a role in the blunted EPO production in anemic
patients with CHF [28], resulting in increased EPO levels but
not as expected for the degree of anemia, suggesting that in
CHF there is both blunted EPO production and resistance
to EPO [28]. Furthermore, the coexistence of CHF with
CKD is associated with reduced EPO production from the
kidney [20], as well as with urinary losses of serum EPO and
transferrin [29, 30], which further deteriorate the anemia.
The renin-angiotensin system seems also to be involved
in the control of erythropoiesis. Angiotensin II reduces renal
blood ﬂow, increases the oxygen demands, and thereby stim-
ulates EPO production [24]. It also stimulates the prolifera-
tion of normal bone marrow early erythroid progenitors in
a direct manner [31]. Both ACE inhibition and angiotensin
receptor blockade decrease erythropoiesis, causing a modestISRN Hematology 3
RAAS activation
Increased renal 
oxygen uptake
Increased plasma 
volume Reduced RBC production
Anemia
Ventricular failure          Reduced arterial ﬂow
Increased EPO
production
Decreased 
EPO 
production
Peritubular
hypoxia
Chronic 
kidney 
disease
Suppression of 
bone marrow 
erythropoiesis 
Reduced iron 
availability
Resistance to EPO
Activation of proinﬂammatory cytokines
(IL-6, TNF-α)
Figure 1: Pathophysiological mechanisms contributing to anemia in chronic heart failure patients. (RAAS: renin-angiotensin-aldosterone
system, IL-6: interleukin-6, TNF-α: tumor necrosis factor alpha, EPO: erythropoietin, RBC: red blood cells).
reduction in Hb, up to 0.3g/dL [14, 32]. This suppression
is attributed to a mild reduction of EPO production and
also to prevention of hematopoiesis inhibitor N-acetyl-ser-
yl-aspartyl-lysyl-proline (AcSDKP) breakdown. AcSDKP is
normally degraded by the amino terminal catalytic domain
of ACE. ACE inhibition should be expected to cause a mild
reduction of erythropoiesis, although various knockout mice
models,involvingdiﬀerentACEcomponents,donotsupport
this theory [33].
Iron deﬁciency is common in patients with CHF espe-
cially when accompanied by CKD [34], whereas vitamin B12
and folic acid deﬁciencies or iron overload are not. It is of
interest that the incidence of iron deﬁciency is increasing
with the severity of heart failure [35]. In half cases, iron de-
ﬁciency is absolute (with low transferrin saturation and ser-
um ferritin, usually associated with decreased iron stores and
reduced iron deposits in the bone marrow). In the other half
casesirondeﬁciencyisfunctional-relative(withlowtransfer-
rin saturation and normal or elevated serum ferritin, usually
associated with normal or elevated iron stores and iron de-
posits in the bone marrow) [36]. It has been reported that in
17% of anemic patients with CHF the iron deﬁciency is both
absolute and functional [35].
There are many causes of absolute iron deﬁciency as-
sociatedwithCHF,especiallyincoexistencewithCKD.These
include
(1) low iron intake (due to low protein diets and ano-
rexia),
(2) gastrointestinal blood loss (due to platelet dysfunc-
tion or coagulation abnormalities; caused by platelet
inhibitors, anticoagulants, or uremia),
(3) iron malabsorption (due to either CHF or uremia re-
lated-bowel edema, causing intestinal cell dysfunc-
tion, or to proton pump inhibitors or to phosphate
binders, that also bind iron),
(4) removal of blood for tests.
In CHF the functional iron deﬁciency is related to iron
disuse, resembling anemia of chronic disease, as evidenced
by iron acquisition by the reticuloendothelial system [37]. In
patients with severe CHF, elevation of several inﬂammatory
cytokines serum levels has been found. Among them, in-
terleukin-1 (IL-1), interleukin-6 (IL-6), tumor necrosis fac-
tor-α (TNF-α), and less frequently interleukin-18 (IL-18)
seem to be the most important, whereas IL-6-induced hep-
cidin expression also participates in the phenomenon [14,
38, 39]. This inﬂammatory process causes reduced EPO pro-
duction, through activation of GATA 2 binding protein and
nuclear factor-κB, and impaired response to bone marrow
erythroblasts. It also causes hepcidin-induced blockade of
iron absorption from the gut and iron trapping in retic-
uloendothelial system’s stores. Hepcidin is an acute phase
antibacterial protein, induced by IL-6, through JAK/Stat3
pathway, released from the liver and excreted from the ur-
ine.Therefore,inCHFwithaconcomitantCKD,thereisare-
duced hepcidin removal from the kidney, implying a further
increase of its levels. Hepcidin inhibits ferroportin, a protein
expressed on intestinal cells, macrophages, and hepatocytes
that releases the iron from those cells into the blood. Hep-
cidin-inducedinhibitionofferroportincausesdecreasediron
absorption from the gut and blockade of iron release from
its stores, in hepatocytes and macrophages, into the blood.
This implies inadequate iron delivery to the bone marrow
erythroblasts, although the total stores may be adequate,4 ISRN Hematology
causing a functional iron deﬁciency. Furthermore hepcidin
seems to exert a direct inhibitory eﬀect on erythroblast pro-
liferation and survival [40].
Iron metabolism is crucial for energy production in the
body and most importantly for cells with high energy de-
mands, such as cardiomyocytes [34]. Iron plays a crucial role
in oxygen transportation (as a component of Hb), oxygen
storage (as a component of myoglobin), oxidative metabo-
lism (as a component of oxidative enzymes and respiratory
chain processes), and in metabolism of lipids, carbohydrates,
nucleicacids,collagen,tyrosine,andcatecholamines[41,42].
In CHF, an energy-starved situation, several disorders of iron
metabolism have been observed. Iron deﬁciency, absolute or
functional,canimpairoxidativemetabolism,cellularenerge-
tic, and cellular immune mechanisms. Iron deﬁciency in rat
hearts causes mitochondrial ultrastructural aberrations, ir-
regular sarcomere organization, and release of cytochrome C
[43]. In addition, experimental animal models with severe
iron deﬁciency have major disruption in energy production
causing cardiac damage, with diastolic dysfunction and
heart failure, accompanied by reduced EPO and increased
TNF-α serum levels and worsening of molecular signaling
pathways. Those defects may participate in the transition
from adaptive cardiac hypertrophy to permanent cardiac
impairment in chronic iron deﬁciency [44]. On the other
hand, iron seems to have anti-inﬂammatory eﬀects. It has
been shown that hemodialysis patients receiving EPO with
IV iron supplementation had lower inﬂammation markers
(lower levels of proinﬂammatory TNF-α and free radicals,
as expressed by total peroxides, and higher levels of anti-
inﬂammatory interleukin-4) compared to patients receiving
EPO alone [45]. Furthermore iron deﬁciency anemia seems
to enhance red cell oxidative stress [46] and has been as-
sociated with lower peak oxygen consumption and higher
ratios of ventilation to carbon dioxide production [35]. In
a recent study the disordered iron homeostasis has been
identiﬁed as an independent risk factor for death [35].
Another eﬀect of iron deﬁciency on CHF patients is the
consequent thrombocytosis. CHF is a hypercoagulable state
[47], where the co-existence with iron deﬁciency-related
thrombocytosis [48] increases the risk of thrombosis and the
mortality rate [49]. Furthermore, it has been shown that the
concomitant administration of IV iron with EPO (which can
cause iron deﬁciency) in hemodialysis patients signiﬁcantly
reduces the platelet counts, compared to patient receiving
EPO alone [50]. It has also been shown that the use of ery-
thropoiesis-stimulating agents (ESAs) in iron-deﬁcient pa-
tients increases the risk of thrombocytosis and thrombosis
[51].
Except iron disuse, inﬂammatory cytokines may cause
EPOresistanceinanemicCHFpatients.Ithasbeensuggested
that there is a diminished responsiveness of erythroid cells
to EPO, being accompanied by increased levels of inﬂam-
matory cytokines, such as IL-6, soluble TNF receptor 2, and
TNF-α levels [52, 53]. Their activation does not result in
EPO receptor downregulation, but in blunted EPO-induced
JAK-STAT signaling [52]. This is conﬁrmed by the partial
abrogation of the inhibitory eﬀects of anaemic sera on ery-
throid colony growth by anti-TNF-α neutralising antibodies
[53]. Furthermore, IL-6-induced hepcidin exerts a direct
inhibitory eﬀect on erythroblast proliferation and survival
[40].
Another factor contributing to anemia of CHF patients
is NO. Endothelial dysfunction associated with heart failure
may alter endothelial NO synthase activity, hence further
augmenting myocardial dysfunction due to increased oxida-
tive stress [54]. Paralleling these cardiodepressive actions,
NO seems to have a direct inhibitory eﬀect on bone mar-
row hematopoietic activity [55, 56]. Furthermore, it is of
interest that NO inhibits blood cell formation in nonisch-
emic murine CHF, whereas inﬂammatory cytokines, such as
TNF-α, impair hematopoiesis in CHF following myocardial
infraction [57].
A recent study suggests that vitamin D deﬁciency is inde-
pendently associated with anemia in end-stage heart failure,
based on the fact that vitamin D may stimulate erythro-
poiesis. On this study circulating 1,25-dihydroxyvitamin D
was a better predictor of anemia than circulating 25-hydro-
xyvitamin D. Prospective randomized studies with adminis-
tration of vitamin D will have to clarify if the association of
vitamin D deﬁciency with anemia is causal [58].
In conclusion anemia in CHF is multifactorial. Two ma-
jor factors contributing and exacerbating to its appearance
are kidney dysfunction and iron deﬁciency. In 2003 this ab-
normality was described as cardio renal anemia syndrome
(CRAS) [6], whereas the correction of anemia could play a
major role in this vicious circle in improving the severity of
CHF. In the last years, the role of iron has been recognized,
asamajorcomponentofmanyenergy-producingsystems.In
view of a possible independent association of iron deﬁciency
and cardiac failure, renal failure and anemia, the same au-
thors rename the syndrome as cardiorenal anemia iron de-
ﬁciency (CRAID) syndrome [6].
4.TreatmentofAnemiainHeartFailure
CHF is not just a hemodynamic disorder. It is the ﬁnal com-
mon pathway of other conditions, where renal failure and
anemiacontributetotheprogressiontoamoreseveredisease
status. They also could be potential targets for intervention.
Since the two major components of CHF anemia are iron
deﬁciency and reduced EPO activity (absolute or functional
in both cases), the main goals of intervention would be to
increase their levels. Anemia treatment strategies in heart
failure patients include erythropoiesis-stimulating agents
(ESAs) and red blood cell transfusions. Iron replacement in
iron-deﬁcient patients with or without anemia has also been
investigated. Before starting any treatment for anemia in
CHF,itisnecessarytoexcludeandtreat,ifpossible,anyother
causes of anemia, such as active bleeding, hemolysis, vitamin
B12orfolatedeﬁciency,orevenmorechronicsituationssuch
as myelodysplastic syndromes and other malignancies.
Health Services Research & Development Service’s Evi-
dence-based Synthesis Program has collected the literature
from 1949 until November 2010 and published a review re-
garding the treatment of anemia in CHF and coronary heart
disease patients [59]. Despite the association with poorerISRN Hematology 5
outcomes, it remains unclear whether treating anemia or
iron deﬁciency may improve outcomes.
It has been suggested that a small reduction of Hb levels
may worsen the outcomes and symptoms of CHF, whereas
the correction of anemia may improve NYHA classiﬁcation,
LVEF, LVH, and diuretic response [60–63]. Treatment has
been centered on administration of erythropoiesis-stimula-
ting agents (ESAs) and parenteral iron supplementation, but
most studies are poorly powered and therefore with limited
validity. On the other hand, the only way to cause a rapid
increase of Ht and therefore tissue oxygenation is the blood
transfusion. Nevertheless, the only recommendations refer-
ringtoanemiaofCHFsuggesttreatinganycorrectablecauses
of anemia, if this is evitable, such as iron, folate, or vitamin
B12 deﬁciencies [64]. The goal of Hb correction is also not
well deﬁned. Transfusion of packed red cells in Hb values
lower than 9g/dL or Ht less than 30% may be suggested, but
in the setting of acute coronary syndromes this has been as-
sociated with higher mortality [65].
There are many data supporting that iron deﬁciency may
contribute to the increased mortality in CHF patients. It
has also been shown that correction of iron deﬁciency could
improvesymptomsandstatusofthesyndrome.Nevertheless,
this has not been adequately conﬁrmed [34]. There are se-
veral studies in CHF, with iron deﬁciency, with and without
anemia, suggesting that correction of iron deﬁciency, using
IV preparations, could improve symptoms and signs of CHF,
such as S -wave, E/E  ratio, peak systolic strain rate, NYHA
class, 6-minute walk distance, even without improvement of
EF or rise of Hb levels, without major side eﬀects [66–70]. It
is suggested, with high evidence, that correction of iron deﬁ-
ciencycanimproveexercisetoleranceandduration,aswellas
the quality of life, in patients with stable CHF and mild CKD
[59]. There are also other studies suggesting that anemia in
CHF can be corrected only with IV iron and not the oral
forms [71–74], whereas long-term oral iron does not seem to
improveanyCHFparameters[75,76].Thisseemsreasonable
since in CHF there is increased hepcidin expression that
blocks iron use, even if it is absorbed. In general terms it is
preferredtoadministrateIVinsteadoforaliron,eventhough
it can cause oxidative stress. When using intravenous pre-
parations, the majority of the dose is deposited in long-term
storage. There is a small portion of this iron that is rapidly
bound to transferrin and available for transport to the bone
marrow, bypassing the restrictions on iron release imposed
by hepcidin. The use of large amounts of iron, delivered
over minutes or hours as pulse therapy, could lead to poor
utilization of this iron with tissue deposition, free radical
formation, and increased risk of infection, because of a
decrease in cellular immunity and promotion of bacterial
growth [69]. Other concerns of iron administration have
to do with an increased risk of coronary heart disease, but
s t i l lh a v en o tb e e nc o n ﬁ r m e d[ 34]. In conclusion, there are
not eﬃcient data proving evidence that iron administration
in non-iron-deﬁcient patients with CHF could improve the
cardiac disease. It is however of great value to recognize iron
deﬁciency, even in the absence of anemia and to correct it.
Regarding ESAs, there are only pilot studies for their
use in the treatment of anemia of CHF. Uncontrolled
hypertensionandirondeﬁciencyarecontraindications.They
are commonly used with simultaneous administration of
IV iron, giving promising results in ameliorating symptoms
and improving cardiac function, but only with very limited
evidence [77, 78]. Moreover, the EPO receptor is present
in many nonerythropoietic tissues, including myocardium,
endothelium, vascular smooth muscle cells, and neurons,
where EPO has shown tissue protective properties, because
of its antiapoptotic action [78]. Treatment with EPO in
excitable murine and human left ventricular muscle prepa-
r a t i o n sh a v er e s u l t e di na ni n c r e a s ei nt w i t c ht e n s i o na n d
in peak sarcomere shortening. This suggests that EPO ex-
hibits direct positive inotropic and lusitropic eﬀects in car-
diomyocytes and ventricular muscle preparation, being me-
diated through PI3-K and PKCε isoform signalling, to
directly aﬀect both calcium release dynamics and myoﬁla-
mentfunction[79].Therefore,therecouldbeanextraroleof
EPOinamelioratingsymptoms,inadditiontoimprovingHb
levels. The major concern of EPO administration, based on
hemodialysisexperience,hastodowithapossibleincreaseof
thrombotic risk, especially by overzealous correction of ane-
mia or when iron-deﬁciency-associated thrombocytosis co-
exists. At present, there are not clearly deﬁned targets of Hb
in CKD anemia, although an Hb level of 10g/dL seems to be
a widely accepted goal.
Recently,therehave been many studies of anemia in CHF
patients with an eﬀort to improve Hb levels. There have been
u s e dE S Aa n do r a lo rI Vi r o na n de v e nI Vi r o nw i t h o u tE S A ,
that have shown a positive eﬀect on hospitalization, NYHA
functional class, cardiac and renal function, quality of life,
exercise capacity, and reduced BNP, without any increase
in cardiovascular damage related to the therapy. However,
adequately powered long-term placebo-controlled studies of
ESA and IV iron in CHF are still needed and are currently
being carried out [80]. Nevertheless, until recently, there is
highevidencethattheuseofESAinstableCHFpatientswith
seriousrenaldiseasedidnothaveanyparticulareﬀectoncar-
diovascular events, whereas there is moderate evidence that
their use might have a negative impact on the survival [59].
Recent studies have recognized that dilutional anemia is
highly prevalent in CHF patients. In this regard, arginine va-
sopressin antagonists might be an attractive treatment op-
tion, by increasing aquaresis.Until now, thereis only indirect
evidence supporting a rationale for their use. Therefore, fu-
ture clinical research should explore the role of arginine va-
sopressin pathway activation in determining dilutional ane-
mia and, ultimately, assess it as a therapeutic target [81].
Anemia is common in patients with heart disease. The
evidence base to date does not convincingly support a role
for ESAs for anemia correction. On the other hand, iron
treatment may help ameliorate symptoms over the short
term in patients with symptomatic heart failure. The role of
blood transfusions remains understudied and unclear [59].
5. Conclusions
It seems that anemia exacerbates CHF, causing a vicious
circle, where renal dysfunction and neurohormonal and6 ISRN Hematology
proinﬂammatory cytokine activation participate in the
developmentofanemia.Ontheotherhand,anemiaincreases
myocardial workload and worsens cardiac dysfunction. So,
it is important to recognize any possible causes of anemia.
It would also be beneﬁcial to treat them, if possible. Ad-
ministration of iron and ESAs seems to be promising, since
they can both also improve factors other than anemia, but
still there are many questions to be answered. These mainly
concern their safety, the goals in Hb elevation, and probably
their cost. Further studies are required to understand the
association of anemia with CHF outcomes, to recognize the
impact of anemia improvement, to asses when to initiate and
whentoceasethetreatment,andﬁnallytoestimatethesafety
of these interventions.
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